Format

Send to

Choose Destination
Clin Infect Dis. 2017 Mar 15;64(suppl_1):S13-S17. doi: 10.1093/cid/ciw826.

Leading Antibacterial Laboratory Research by Integrating Conventional and Innovative Approaches: The Laboratory Center of the Antibacterial Resistance Leadership Group.

Author information

1
Public Health Research Institute Center, New Jersey Medical School-Rutgers University, Newark.
2
Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina.
3
Louis Stokes Cleveland Department of Veterans Affairs Medical Center, and.
4
Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio.
5
Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, and.
6
Division of Infectious Diseases, Department of Medicine, Mayo Clinic, Rochester, Minnesota ; and.
7
Center for Biostatistics in AIDS Research and the Department of Biostatistics, Harvard University, Boston, Massachusetts.

Abstract

The Antibacterial Resistance Leadership Group (ARLG) Laboratory Center (LC) leads the evaluation, development, and implementation of laboratory-based research by providing scientific leadership and supporting standard/specialized laboratory services. The LC has developed a physical biorepository and a virtual biorepository. The physical biorepository contains bacterial isolates from ARLG-funded studies located in a centralized laboratory and they are available to ARLG investigators. The Web-based virtual biorepository strain catalogue includes well-characterized gram-positive and gram-negative bacterial strains published by ARLG investigators. The LC, in collaboration with the ARLG Leadership and Operations Center, developed procedures for review and approval of strain requests, guidance during the selection process, and for shipping strains from the distributing laboratories to the requesting investigators. ARLG strains and scientific and/or technical guidance have been provided to basic research laboratories and diagnostic companies for research and development, facilitating collaboration between diagnostic companies and the ARLG Master Protocol for Evaluating Multiple Infection Diagnostics (MASTERMIND) initiative for evaluation of multiple diagnostic devices from a single patient sampling event. In addition, the LC has completed several laboratory-based studies designed to help evaluate new rapid molecular diagnostics by developing, testing, and applying a MASTERMIND approach using purified bacterial strains. In collaboration with the ARLG's Statistical and Data Management Center (SDMC), the LC has developed novel analytical strategies that integrate microbiologic and genetic data for improved and accurate identification of antimicrobial resistance. These novel approaches will aid in the design of future ARLG studies and help correlate pathogenic markers with clinical outcomes. The LC's accomplishments are the result of a successful collaboration with the ARLG's Leadership and Operations Center, Diagnostics and Devices Committee, and SDMC. This interactive approach has been pivotal for the success of LC projects.

KEYWORDS:

antibacterial resistance; bacterial strains.; biorepository; diagnostics and devices; drug testing

PMID:
28350898
PMCID:
PMC5848373
DOI:
10.1093/cid/ciw826
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center